Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2026
Reporting Period: The filing announces financial results for the three and twelve months ended December 31, 2025.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, no numerical values for these metrics are available in the source text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It only confirms the issuance of a press release containing the results for the period ended December 31, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a conference call to be held at 8:00 AM ET on March 12, 2026, to discuss the results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q4 and FY 2025.
- Verify the details of the conference call held on March 12, 2026, for management's outlook and guidance.
- Confirm whether the press release contains any updates on debt covenants or liquidity positions.
- Check for any forward-looking statements or risk factors disclosed in the referenced press release.